Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLSE Stock Forecast 2025-2026
$14.40
Current Price
$975.85M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PLSE Price Targets
+52.8%
To High Target of $22.00
+52.8%
To Median Target of $22.00
+52.8%
To Low Target of $22.00
PLSE Price Momentum
-6.9%
1 Week Change
-16.7%
1 Month Change
-13.5%
1 Year Change
-17.3%
Year-to-Date Change
-42.4%
From 52W High of $25.00
+4.6%
From 52W Low of $13.77
📊 TOP ANALYST CALLS
Did PLSE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pulse Biosciences is one of their latest high-conviction picks.
Latest PLSE Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, PLSE has a bullish consensus with a median price target of $22.00 (ranging from $22.00 to $22.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $14.40, the median forecast implies a 52.8% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Suraj Kalia at Oppenheimer, projecting a 52.8% upside. Conversely, the most conservative target is provided by Suraj Kalia at Oppenheimer, suggesting a 52.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLSE Analyst Ratings
1
Buy
0
Hold
0
Sell
PLSE Price Target Range
Low
$22.00
Average
$22.00
High
$22.00
Current: $14.40
Latest PLSE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLSE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2025 | Oppenheimer | Suraj Kalia | Outperform | Initiates | $22.00 |
| Sep 21, 2022 | Maxim Group | Anthony Vendetti | Hold | Downgrade | $N/A |
| May 13, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Neutral | Downgrade | $N/A |
| Apr 1, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.50 |
| Apr 1, 2022 | Stephens & Co. | Chris Cooley | Overweight | Maintains | $12.00 |
| Feb 10, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $20.00 |
| Nov 16, 2021 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $43.00 |
| Jul 27, 2021 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Mar 11, 2021 | Maxim Group | Buy | Initiates | $N/A | |
| Jan 26, 2021 | HC Wainwright & Co. | Buy | Maintains | $40.00 | |
| May 12, 2020 | HC Wainwright & Co. | Buy | Upgrade | $16.00 | |
| May 12, 2020 | H.C. Wainwright | Buy | Upgrade | $N/A | |
| Feb 14, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Feb 14, 2020 | H.C. Wainwright | Neutral | Downgrade | $N/A | |
| Feb 25, 2019 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Feb 25, 2019 | H.C. Wainwright | Buy | Initiates | $N/A |
Pulse Biosciences Inc. (PLSE) Competitors
The following stocks are similar to Pulse Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pulse Biosciences Inc. (PLSE) Financial Data
Pulse Biosciences Inc. has a market capitalization of $975.85M with a P/E ratio of -15.7x. The company generates $86,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -23,682.6% and return on equity of -87.0%.
Valuation Metrics
Market Cap
$975.85M
Enterprise Value
$929.19M
P/E Ratio
-15.7x
PEG Ratio
-0.4x
Price/Sales
11,142.3x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
-224.4%
Operating Margin
-23,682.6%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.8%
Current Ratio
10.0x
Debt/Equity
8.5x
ROE
-87.0%
ROA
-48.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pulse Biosciences Inc. (PLSE) Business Model
About Pulse Biosciences Inc.
What They Do
Develops bioelectric medicine for medical treatments.
Business Model
The company utilizes its proprietary Nano-Pulse Stimulation technology to provide innovative, non-invasive treatments primarily focused on dermatology and oncology. It generates revenue by offering advanced medical solutions that improve patient outcomes and reduce invasiveness compared to traditional therapies.
Additional Information
Pulse Biosciences is positioned at the forefront of personalized medicine and targeted treatment strategies, with the potential to revolutionize treatment methods in aesthetics and medical disorders. Its technology's significance is growing in the evolving landscape of healthcare, emphasizing the demand for effective and less invasive medical solutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
75
CEO
Mr. Paul Arthur LaViolette
Country
United States
IPO Year
2016
Website
www.pulsebiosciences.comPulse Biosciences Inc. (PLSE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +6.45% and -82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 05, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Pulse Biosciences, Inc. will hold its Q3 2025 earnings call on November 5, 2025, at 4:30 PM EST, featuring CEO Paul LaViolette and CFO Jon Skinner.
Why It Matters
Pulse Biosciences' Q3 earnings call could reveal critical financial performance insights and future guidance, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences (Nasdaq: PLSE) announced Q3 2025 results and initiated the PRECISE-BTN clinical study for treating benign thyroid nodules using its nPulse technology.
Why It Matters
Pulse Biosciences' initiation of a multi-center clinical study for treating benign thyroid nodules with its nPulse technology signals potential revenue growth and market expansion, impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences, Inc (PLSE) reported a quarterly loss of $0.29 per share, beating the Zacks Consensus Estimate of $0.31, but worsening from a loss of $0.16 per share a year prior.
Why It Matters
Pulse Biosciences' smaller-than-expected loss indicates potential operational improvements, which could boost investor confidence and impact stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Pulse Biosciences, Inc. (Nasdaq: PLSE) will present at the Stifel 2025 Healthcare Conference on November 13, 2025, at 2:40 pm ET, and will also participate in the Piper Sandler conference.
Why It Matters
Pulse Biosciences' participation in major investor conferences can boost visibility, attract potential investors, and signal confidence in its innovative technology, impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences (Nasdaq: PLSE) has enrolled its first patient in the NANOCLAMP AF Study for atrial fibrillation treatment using its nPulse™ technology, following recent FDA approval.
Why It Matters
Pulse Biosciences' successful patient enrollment in the NANOCLAMP AF Study signals progress in atrial fibrillation treatment, potentially enhancing growth prospects and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences, Inc. (Nasdaq: PLSE) will report Q3 2025 financial results on November 5, 2025, after market close, followed by a conference call at 1:30 PM PT.
Why It Matters
Pulse Biosciences' upcoming financial results and business updates may impact stock performance, offering insights into its growth and the effectiveness of its innovative nsPFA technology.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PLSE Stock
What is Pulse Biosciences Inc.'s (PLSE) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Pulse Biosciences Inc. (PLSE) has a median price target of $22.00. The highest price target is $22.00 and the lowest is $22.00.
Is PLSE stock a good investment in 2026?
According to current analyst ratings, PLSE has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLSE stock?
Wall Street analysts predict PLSE stock could reach $22.00 in the next 12 months. This represents a 52.8% increase from the current price of $14.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pulse Biosciences Inc.'s business model?
The company utilizes its proprietary Nano-Pulse Stimulation technology to provide innovative, non-invasive treatments primarily focused on dermatology and oncology. It generates revenue by offering advanced medical solutions that improve patient outcomes and reduce invasiveness compared to traditional therapies.
What is the highest forecasted price for PLSE Pulse Biosciences Inc.?
The highest price target for PLSE is $22.00 from Suraj Kalia at Oppenheimer, which represents a 52.8% increase from the current price of $14.40.
What is the lowest forecasted price for PLSE Pulse Biosciences Inc.?
The lowest price target for PLSE is $22.00 from Suraj Kalia at Oppenheimer, which represents a 52.8% increase from the current price of $14.40.
What is the overall PLSE consensus from analysts for Pulse Biosciences Inc.?
The overall analyst consensus for PLSE is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $22.00.
How accurate are PLSE stock price projections?
Stock price projections, including those for Pulse Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 3:49 AM UTC